Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy

We explored the safety and efficacy of bortezomib given as single agent in patients with untreated or relapsed/refractory acute myeloid leukemia (AML), unfit for conventional chemotherapy. Fourteen patients were treated with bortezomib 1.5 mg/m(2) administered twice weekly for two weeks, every 3 wee...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sarlo, Chiara, Buccisano, Francesco, Maurillo, Luca, Cefalo, Mariagiovanna, Di Caprio, Luigi, Cicconi, Laura, Ditto, Concetta, Ottaviani, Licia, Di Veroli, Ambra, Del Principe, Maria Ilaria, Grasso, Maria Assunta, Nasso, Daniela, De Santis, Giovanna, Amadori, Sergio, Venditti, Adriano
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2013
Assuntos:
Clinical Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3655652/
https://ncbi.nlm.nih.gov/pubmed/23738080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2013/705714
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados